ENDOMETRIAL NEOPLASMS
Clinical trials for ENDOMETRIAL NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL NEOPLASMS trials appear
Sign up with your email to follow new studies for ENDOMETRIAL NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Smart drug targets HER2 cancers in new trial
Disease control OngoingThis study tests an experimental drug called disitamab vedotin in people with advanced head and neck, lung, endometrial, or ovarian cancers that have a marker called HER2. The drug is designed to stick to cancer cells and kill them. About 120 participants will receive the drug ev…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 26, 2026 10:28 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called E7386 combined with other anticancer drugs in people with advanced solid tumors, including endometrial, liver, and colorectal cancers. The goal is to find safe and effective doses and see if the combination can shrink tumors. About 300 participa…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated May 26, 2026 10:26 UTC
-
New drug combo shows promise for advanced endometrial cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy, followed by maintenance durvalumab with or without the targeted drug olaparib, can help people with newly diagnosed advanced or recurrent endometrial cancer live longer without their cance…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
Immunotherapy shows promise against tough uterine cancer
Disease control OngoingThis study compares the immunotherapy drug pembrolizumab to standard chemotherapy in 280 women with advanced or recurrent endometrial cancer that has a specific genetic marker (dMMR). The goal is to see if pembrolizumab can better delay cancer growth or improve survival. Particip…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New drug targets Hard-to-Treat HER2 cancers in early trial
Disease control OngoingThis early-stage study tests an experimental drug called BL-M17D1 in 120 adults with advanced solid tumors that have a specific protein (HER2) or a HER2 gene change. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants mus…
Matched conditions: ENDOMETRIAL NEOPLASMS
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated May 18, 2026 12:07 UTC